key: cord-0902038-r9qtzdvk
authors: Peghin, Maddalena; Bouza, Emilio; Fabris, Martina; De Martino, Maria; Palese, Alvisa; Bontempo, Giulia; Graziano, Elena; Gerussi, Valentina; Bressan, Valentina; Sartor, Assunta; Isola, Miriam; Tascini, Carlo; Curcio, Francesco
title: Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19
date: 2021-08-11
journal: Eur J Clin Microbiol Infect Dis
DOI: 10.1007/s10096-021-04335-x
sha: 8a22c1f821106ff4ee33df7d11303558a7f7d652
doc_id: 902038
cord_uid: r9qtzdvk

The aim of the study was to assess reinfection rates in relation to long-term antibody dynamics against SARS-CoV-2 after the first wave. A prospective longitudinal study with monthly serological follow-up during the first 4 months, and then at 6, 8, and 10 months after the disease onset of all recovered adult in- and outpatients with COVID-19 attending Udine Hospital (Italy) from March to May 2020. During the follow-up, reinfections were collected. A total of 546 unselected individuals with COVID-19 acquired from March to May 2020 were included (292 female, mean age 53 years). After a median follow-up of 10 months (IQR 6.2–10.4), reinfection occurred in 6 (1.1%) patients, median age of 44.5 years (IQR 33‒49). All had a previous history of mild COVID-19 (all were healthcare workers) and reinfection occurred a median of 9 months (IQR 8.2‒10.2) after the onset of the first episode. Patients with reinfection were either seronegative (2/56, n = 3.6%), seroreverted (2/137, 1.5%), or seropositive (2/353, 0.6%) (p = 0.085). All reinfections were mild (n = 5) or asymptomatic (n = 1). After reinfection, none of patients developed IgM response and only two had a transitory boosted IgG immunization response. In an unselected population after the first wave of COVID-19, after a prolonged observation period (mean 10 months), reinfection was very uncommon; occurred in patients with a previous history of mild infection, mostly with weak or absent serological response; and manifested with mild or asymptomatic clinical presentation.

Cases of Coronavirus Disease 2019 (COVID- 19) reinfection have been sporadically reported and questions remain on the incidence, time of occurrence, duration, and protective role of immunity after natural infection. [1] [2] [3] [4] [5] Knowledge available on reinfections is still scarce due to the frequently retrospective nature of published reports and the limited follow-ups post-symptom onset. In addition, all studies provide estimates in selected biased populations derived from laboratory testing data sets, specific outbreak settings, or subgroups such as healthcare workers (HCWs), and it is unclear how generalizable and applicable the findings are to an unselected adult population [6] [7] [8] [9] [10] [11] [12] [13] .

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) humoral immunity suggests that more than 90% of seroconversion rates occur after acute primary infection with variable degrees of decline in antibody levels over time [14, 15] . However, the literature available provides limited evidence on the presence of SARS-CoV-2 antibodies as a surrogate of individual protection against reinfection [1] [2] [3] [4] [5] [6] [7] . A better understanding of the long-term dynamics of immune response to SARS-CoV-2 infection and the risk of reinfection would help in defining and monitoring the extent of virus spread and the herd immunity, as well as in identifying the most appropriate public health strategies including vaccination planning to control the of COronaVIrus Disease 19 pandemic [16] .

The aim of this prospective longitudinal study was to comprehensively characterize the relative incidence of COVID-19 reinfections in relation to serological response among individuals who had recovered from COVID-19 after the first wave. The study included a wide spectrum of unselected patients ranging from asymptomatic to severely infected, assessed over a 10-month follow-up period.

We performed the study at Udine Hospital (Italy), a 1000bed tertiary-care teaching hospital identified as a regional referral center for COVID-19 patients and serving approximately 350,000 citizens. Methods and findings are reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement [17] .

The target population was a cohort of all consecutive adult in-and outpatients (≥ 18 years) attending the Infectious Disease Department with a diagnosis of COVID-19 from March 1 (the day of the first COVID-19 diagnosis at our hospital) until May 30, 2020. Further definitions of acute COVID-19 and baseline conditions are summarized in Supplementary Table 1 .

SARS-CoV-2 antibody concentrations were measured at the serological follow-up visits each month (± 15 days) after symptom onset for the first 4 months, and every other month up to 10 months (± 15 days), from March 2020 to February 2021 (CORMOR 3-4® protocol). Patients attending at least two serological follow-ups were included in the study (Fig. 1) .

Clinical reinfection was defined as clinical recurrence of symptoms compatible with COVID-19, accompanied by a positive PCR test (Ct < 35), more than 90 days after the onset of the primary infection, supported by closecontact exposure or outbreak settings, and no evidence of another cause of infection. Epidemiological reinfection was defined as any positive PCR test (Ct < 35) more than 90 days from first episode, regardless of symptoms [18] . Specifically, patients with symptoms or signs of recurrent illness (fever, rhinorrhea, sore throat, cough, dyspnea, sputum, myalgia, fatigue, thoracic pain, vomiting, diarrhea, dysgeusia or anosmia, conjunctivitis, rash) and/or a positive PCR test for SARS-CoV-2 were instructed to contact the research team by phone, in order to schedule a prompt visit (within 24 h) at the infectious disease outpatient clinic or go to the emergency department for medical examination and PCR test for SARS-CoV-2. In addition, during this contact, patients were asked about previous not-reported episodes of symptoms/signs. Systematic SARS-CoV-2 PCR test was performed at regular intervals (every 2/4 weeks) only for healthcare workers (HCWs) in accordance to Hospital and Nursing homes/ long-term facility protocols.

At the time of reinfection, for definitive analysis, we classified patients according to their most recent (within 2 months) antibody status into three groups: (1) seronegative in the absence of any IgM-/IgG-positive serological samples; (2) seroreverted in the presence of a decline in IgM/IgG antibody levels below the positivity threshold after initial seroconversion; and (3) seropositive in the presence of persistence of IgM-/IgG-positive serological sample.

Serum concentrations of the anti-SARS-CoV-2 specific antibodies IgG and IgM were assessed using iFlash-SARS-CoV-2 (Shenzhen YHLO Biotech Co., Ltd., China, distributed in Italy by Pantec SRL), a paramagnetic particle chemiluminescence immunoassay (CLIA) for the determination of IgM and IgG antibodies against SARS-CoV-2 N and S protein. In accordance with the manufacturer's instructions, the IgM and IgG thresholds for positivity were considered to be 10.0 kAU/L. 19 .

Patients' demographic and clinical characteristics were presented with absolute values and percentages for categorical variables and means or medians (standard deviation (SD) or interquartile ranges (IQRs)) for continuous variables. The Shapiro-Wilk test was used to assess whether data were normally or non-normally distributed. Categorical variables were compared using the chi square (χ 2 ) test or Fisher's exact test, while quantitative variables were compared using the t-test or Mann-Whitney U test, as appropriate. Statistical analysis was performed using STATA 16.1.

Overall, during the study period, a total of 1067 patients received the COVID-19 diagnosis. After excluding 211 patients for refusing to participate in the research, 138 nursing home/long-term facility residents who were not capable of giving their consent due to cognitive decline, 38 who were lost to follow-up, 51 for incomplete serological follow-up and 81 deaths, a total of 546 patients were included (Fig. 1) . Demographic and clinical characteristics of patients at baseline are summarized in Table 

A complete description of the serological evolution of the study population is presented in another work that is currently in progress. In brief, the overall seroconversion rate within 2 months was 32% for IgM: 25% in mild cases and 61% in moderate to critical cases. IgM was generally not detected after 4 months (90th percentile equal to 135 days). The overall seroconversion rate for IgG within 2 months was higher for IgG (90%): 91% in mild patients, 100% in moderate to critical patients, and only 54% in asymptomatic cases. About half of the patients (47%) had experienced IgG seroreversion at 10 months, and rates of antibody loss were almost complete (88%) for asymptomatic patients, around half for mild cases (53%) but only 13% for moderate to severe COVID-19.

Patients were followed up for a median of 10 months (IQR, 6.2-10.4). The reinfection rate was 1.1% (6/546). Cases of reinfection occurred at a median of 9 months (IQR 8.2-10.2) after the acute onset of the first episode. The median age was 44.5 years (IQR 33-49) and all were HCWs ( Table 2 ). As reported in Table 2 , all patients experienced mild infection (6/370, 1.6%) during the first episode and manifested mild (n = 5) or asymptomatic (n = 1) reinfections. Reinfection rates did not differ significantly in seronegative (2/56, n = 3.6%), seroreverted (2/137, 1.5%), or seropositive (2/353, 0.6%) patients (p = 0.085) but were significantly higher in HCWs than in non-HCWs (6/119, 5.0% versus 0/385, p < 0.001). Only one patient had a high-titer serological response against SARS-CoV-2 at the time of reinfection (Table 2) (Fig. 2) . After reinfection, none of the patients developed an IgM response and only two had a transitory boosted IgG immunization response (Fig. 2) . After repeating isolation and tracing of close contacts, we found no transmission to other individuals. The serological evolution after the first and second infections is described in Fig. 2 .

Our prospective longitudinal study of an unselected population with COVID-19, acquired during the first wave of the pandemic, with different degrees of severity, shows that there was a very low risk of reinfection after a mean followup of 10 months and that the primary serological response was not accurately predictive of reinfection.

Ideally, episodes of reinfection are confirmed when the primary and secondary episode are caused by different variants of SARS-CoV-2, using whole genomic sequencing [20] . However, there are considerable logistic challenges and these tests are often unavailable [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . In the absence of such molecular confirmation, other criteria of clinical and epidemiological reinfection have recently been proposed and were met by our patients. The overall incidence rate of COVID-19 reinfections documented to date ranges from 0.15 to 2.2% and has proved to be low compared with the incidence rate among naïve patients. Data are generally collected in specific populations, without a prospective search and with shorter follow-up periods compared to that in our study [1-10, 13, 21] . After a prolonged longitudinal follow-up of 10 months, we found that the overall rate of reinfections was 1.1%. Notably, during this period, rates of infection in the general population of the Friuli Venezia Giulia (FVG) Region were high (prevalence 8%; cases 99,730; deaths 3402) [22] .

In our cohort, reinfections have been manifested with low severity and only in patients with a previous history of mild infection, whereas patients with moderate to critical illness did not experience reinfection. These results are in line with available studies suggesting that reinfections are less severe than primary infections and mostly occur in patients with an initial history of asymptomatic or mild COVID-19 [1, 2, 10-12, 23, 24] .

The fact that all our reinfections occurred in HCWs is surprising. This could be due either to a higher grade of exposure to COVID-19 cases or to a more rapid access to SARS-CoV-2 molecular PCR testing compared with the general population [1, 2, 6, 12, 18] .

In the present study, the median age of reinfected patients was low, and none of the elderly (> 65 years) subjects included was reinfected. These findings add those available in recent studies showing conflicting results on the degree of natural humoral protection against reinfection among older people and found high rates of reinfection in the young population. [8, 10, 25, 26] .

It is worth noting that although there is currently no strong evidence that previous SARS-CoV-2 infection reduces the transmission risk [23], we performed tracing of close contacts among our four patients and did not find any secondary cases. As in previous studies, the serological follow-up of our population showed the development of virus-specific antibodies within 2 months in most patients (90%), followed by a waning of antibody responses in the late convalescent period, with an IgG antibody loss of up to 50% at 10 months [14, 23] . Although there is no conclusive evidence that SARS-CoV-2 antibody responses protect against reinfection, it has been observed that they reduce the risk in the case of breakthrough reinfection [1, 7, 10, 18, 25] . In our study, only one reinfected patient maintained a robust humoral response at the time of reinfection. The role of humoral immune memory derived from primary infection as a surrogate of individual protection against reinfection is still controversial [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Interestingly, after reinfection, only two patients presented a transitory boosted IgG immunization response, with no associated change in IgM response. This humoral evolution after reinfection may be the result of a cross-protection associated with primary infection, elicitation of T cell-mediated adaptive immunity, and/or immune evasion due to a genetically distinct form of SARS-CoV-2 [14, 24, 27, 28] .

This study has several limitations. First, it was performed at a single center where a number of patients refused to participate and were lost at the follow-up. Second, in reinfected patients, viral cultures were not performed and genomic sequencing searching for variants was not possible. Third, our rates of reinfection may be underestimated, since asymptomatic reinfections were not routinely checked. However, our hospital was used as a referral center for COVID -19 where the majority of the COVID-19 cases were confirmed, and none of them was admitted during the study period. Fourth, seropositive patients may have at-risk behavior and be less likely to seek medical evaluation if reinfected, but this was not observed in other studies [7] ; furthermore, the high number of HCWs may be associated with a selection bias because HCWs are more likely to self-monitor for any symptoms and to continue to be involved in a research study. Fifth, due to the low number of reinfections, it was not possible to evaluate whether past seroconversion or current antibody persistence determined protection against the risk of reinfection. Lastly, the role of B cell-and T cell-mediated adaptive immunity was not assessed in our study, and, therefore, it was not possible to determine whether protection from reinfection was conferred through the measured antibodies or cellular immunity. However, the complexity of this test prevents routine testing on a large scale.

Most people who have recovered from COVID-19 have a low risk of reinfection; secondary infections may occur mainly in patients with a primary mild COVID-19 infection and with low or absent serological response at the time of reinfection. These findings may suggest that natural humoral protective immunity may be transient and may not confer herd immunity. Given the short supply of vaccine in some countries or settings, public health interventions should be extended as not to prioritize patients with a previous history of SARS-CoV-2 infection except for those at risk for poor outcomes and/or high-risk settings of exposure. Further large-scale standardized longitudinal studies with a longer follow-up focused both on humoral and on cell-mediated adaptive SARS-CoV-2 immunity are needed to determine the longevity of protection after infection for subsequent episodes in order to understand the evolution of the pandemic and to design a vaccination plan, taking into consideration emerging variants of concern.

The online version contains the supplementary material.

The importance and challenges of identifying SARS-CoV-2 reinfections

Antibody status and incidence of SARS-CoV-2 infection in health care workers

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate

Suspected recurrent SARS-CoV-2 infections among residents of a skilled nursing facility during a second COVID-19 outbreak -Kentucky

SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks. medRxiv : the preprint server for health sciences

Association of SARS-CoV-2 seropositive antibody test with risk of future infection

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection

SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. The Lancet. Respiratory medicine

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. The Lancet. Public health

Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19

SARS-CoV-2 antibody response in persons with past natural infection. The New England journal of medicine

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration

Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clinical microbiology and infection : the official publication of the European Society of

Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays? Clinica chimica acta; international journal of clinical chemistry

Centers for Disease Control and Prevention Reinfection with COVID-19

Severe Acute Respiratory Syndrome Coronavirus 2 P.2 lineage associated with reinfection case, Brazil

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks -Connecticut

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Serum antibody profile of a patient with Coronavirus Disease 2019 reinfection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

The authors would like to thank all clinical and